348 related articles for article (PubMed ID: 26772424)
1. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future.
Zhang X; Ng HLH; Lu A; Lin C; Zhou L; Lin G; Zhang Y; Yang Z; Zhang H
Nanomedicine; 2016 May; 12(4):853-869. PubMed ID: 26772424
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma.
Elnaggar MH; Abushouk AI; Hassan AHE; Lamloum HM; Benmelouka A; Moatamed SA; Abd-Elmegeed H; Attia S; Samir A; Amr N; Johar D; Zaky S
Semin Cancer Biol; 2021 Feb; 69():91-99. PubMed ID: 31421265
[TBL] [Abstract][Full Text] [Related]
3. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.
Turato C; Balasso A; Carloni V; Tiribelli C; Mastrotto F; Mazzocca A; Pontisso P
J Control Release; 2017 Dec; 268():184-197. PubMed ID: 29051062
[TBL] [Abstract][Full Text] [Related]
4. Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.
Li M; Zhang W; Wang B; Gao Y; Song Z; Zheng QC
Int J Nanomedicine; 2016; 11():5645-5669. PubMed ID: 27920520
[TBL] [Abstract][Full Text] [Related]
5. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.
Kong FH; Ye QF; Miao XY; Liu X; Huang SQ; Xiong L; Wen Y; Zhang ZJ
Theranostics; 2021; 11(11):5464-5490. PubMed ID: 33859758
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in Asialoglycoprotein Receptor and Glycyrrhetinic Acid Receptor-Mediated and/or pH-Responsive Hepatocellular Carcinoma- Targeted Drug Delivery.
Li YL; Zhu XM; Liang H; Orvig C; Chen ZF
Curr Med Chem; 2021; 28(8):1508-1534. PubMed ID: 32368967
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
8. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine.
Kumar V; Rahman M; Gahtori P; Al-Abbasi F; Anwar F; Kim HS
Expert Opin Drug Deliv; 2021 Jun; 18(6):673-694. PubMed ID: 33295218
[TBL] [Abstract][Full Text] [Related]
9. Graphene quantum dots mediated magnetic chitosan drug delivery nanosystems for targeting synergistic photothermal-chemotherapy of hepatocellular carcinoma.
Chen L; Hong W; Duan S; Li Y; Wang J; Zhu J
Cancer Biol Ther; 2022 Dec; 23(1):281-293. PubMed ID: 35323086
[TBL] [Abstract][Full Text] [Related]
10. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Zhu AX
Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
[TBL] [Abstract][Full Text] [Related]
11. Drug delivery strategy in hepatocellular carcinoma therapy.
Yang S; Cai C; Wang H; Ma X; Shao A; Sheng J; Yu C
Cell Commun Signal; 2022 Mar; 20(1):26. PubMed ID: 35248060
[TBL] [Abstract][Full Text] [Related]
12. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma.
Gong J; Chuang J; Cho M; Toomey K; Hendifar A; Li D
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718047
[TBL] [Abstract][Full Text] [Related]
13. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
14. Chitosan-based nanoscale delivery systems in hepatocellular carcinoma: Versatile bio-platform with theranostic application.
Karimi K; Mojtabavi S; Tehrany PM; Nejad MM; Rezaee A; Mohtashamian S; Hamedi E; Yousefi F; Salmani F; Zandieh MA; Nabavi N; Rabiee N; Ertas YN; Salimimoghadam S; Rashidi M; Rahmanian P; Hushmandi K; Yu W
Int J Biol Macromol; 2023 Jul; 242(Pt 3):124935. PubMed ID: 37230442
[TBL] [Abstract][Full Text] [Related]
15. Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma.
Swamy SG; Kameshwar VH; Shubha PB; Looi CY; Shanmugam MK; Arfuso F; Dharmarajan A; Sethi G; Shivananju NS; Bishayee A
Target Oncol; 2017 Feb; 12(1):1-10. PubMed ID: 27510230
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes.
Jang JW; Song Y; Kim KM; Kim JS; Choi EK; Kim J; Seo H
BMC Cancer; 2016 Oct; 16(1):810. PubMed ID: 27756242
[TBL] [Abstract][Full Text] [Related]
17. A supramolecular nanoparticle system based on β-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma.
Xiong Q; Cui M; Bai Y; Liu Y; Liu D; Song T
Colloids Surf B Biointerfaces; 2017 Jul; 155():93-103. PubMed ID: 28411478
[TBL] [Abstract][Full Text] [Related]
18. The Application of Pre-clinical Animal Models to Optimise Nanoparticulate Drug Delivery for Hepatocellular Carcinoma.
Zhang Z; Song L; Guo J
Pharm Nanotechnol; 2018; 6(4):221-231. PubMed ID: 30277174
[TBL] [Abstract][Full Text] [Related]
19. Potential targets and therapeutics for cancer stem cell-based therapy against drug resistance in hepatocellular carcinoma.
Zhao H; Ling Y; He J; Dong J; Mo Q; Wang Y; Zhang Y; Yu H; Tang C
Drug Resist Updat; 2024 May; 74():101084. PubMed ID: 38640592
[TBL] [Abstract][Full Text] [Related]
20. Targeting integrins in hepatocellular carcinoma.
Wu Y; Qiao X; Qiao S; Yu L
Expert Opin Ther Targets; 2011 Apr; 15(4):421-37. PubMed ID: 21332366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
